Benefitting From Immunotherapy in CRC

Pashtoon M. Kasi, MD, MBBS, MS, discusses the patient populations with colorectal cancer that are likely to benefit from immunotherapy treatment.

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at the Mayo Clinic, discusses the populations of patients with colorectal cancer (CRC) that are likely to benefit from immunotherapy treatment.

Previously, immunotherapy was not an option for patients with CRC, but now subsets of patients has been identified that respond to this type of treatment, Kasi says. Patients who can benefit from immunotherapy include patients with mismatch repair deficient, microsatellite instability-high, or Lynch syndrome-associated CRC.